Price$10.49-0.28 (-2.60%)
01:45 PM07:45 PM
News · 26 weeks57-43%
2025-11-092026-05-03
Mix3590d
- Insider13(37%)
- Other9(26%)
- SEC Filings9(26%)
- Earnings3(9%)
- Analyst1(3%)
Latest news
25 items- PRBeta Bionics to Present at the Bank of America Securities Health Care ConferenceIRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 12, 2026 at 2:20 pm Eastern Time (11:20 am Pacific Time). A live audio webcast of the presentation will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay following the event. About Beta Bionics Beta Bionics, Inc. is a commercial-stage medical device company engaged in the des
- SECSEC Form 10-Q filed by Beta Bionics Inc.10-Q - Beta Bionics, Inc. (0001674632) (Filer)
- SECBeta Bionics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Beta Bionics, Inc. (0001674632) (Filer)
- PRBeta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 GuidanceIRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2026 and raised its full year guidance for the year ending December 31, 2026. First Quarter 2026 Financial Highlights & Key Metrics Net sales of $27.6 million, up 57% compared to $17.6 million in the first quarter of 2025. Durable Medical Equipment (DME) channel net sales of $16.9 million, up 22% compared to $13.8 million in the first quarter of 2025.Pharmacy Benefit Plan (PBP) channel net sales of $10.7 million, up 181% compared to $3.8 million in the fir
- SECSEC Form DEFA14A filed by Beta Bionics Inc.DEFA14A - Beta Bionics, Inc. (0001674632) (Filer)
- SECSEC Form DEF 14A filed by Beta Bionics Inc.DEF 14A - Beta Bionics, Inc. (0001674632) (Filer)
- PRBeta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes CareIRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Beta Bionics today announced the launch of Bionic Insights™, an innovative new feature within its Bionic Reports, designed to help healthcare providers (HCPs) make more informed, personalized treatment recommendations for people living with diabetes. As the first and only insulin pump company to deliver this level of intelligent reporting, Beta Bionics is redefining how clinicians interpret patient data. Bionic Insights goes beyond traditional glucose reporting by surfacing clinically relevant indicators, patient activities and system events that directly influence outcomes – giving providers unprecedented clarity into what's working and
- PRBeta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2026 financial results after the financial markets close on Tuesday, April 21, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's first quarter 2026 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. To
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.SCHEDULE 13G/A - Beta Bionics, Inc. (0001674632) (Subject)
- INSIDERChief Medical Officer Russell Steven Jon sold $30,069 worth of shares (1,025 units at $29.34), decreasing direct ownership by 0.57% to 178,071 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERChief Commercial Officer Hopman Mark sold $88,304 worth of shares (2,917 units at $30.27), decreasing direct ownership by 2% to 136,216 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Commercial Officer Hopman Mark4/A - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by President & CEO Saint Sean4/A - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Medical Officer Russell Steven Jon4/A - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Product Officer Mensinger Mike4/A - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Financial Officer Feider Stephen4/A - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERChief Commercial Officer Hopman Mark sold $4,084 worth of shares (353 units at $11.57), decreasing direct ownership by 0.25% to 139,133 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- SECSEC Form 144 filed by Beta Bionics Inc.144 - Beta Bionics, Inc. (0001674632) (Subject)
- INSIDERChief Medical Officer Russell Steven Jon was granted 109,105 shares and sold $12,683 worth of shares (1,026 units at $12.36), increasing direct ownership by 152% to 179,096 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERPresident & CEO Saint Sean was granted 343,269 shares and sold $41,832 worth of shares (3,384 units at $12.36), increasing direct ownership by 347% to 437,809 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERChief Commercial Officer Hopman Mark was granted 109,105 shares and sold $10,310 worth of shares (834 units at $12.36), increasing direct ownership by 347% to 139,486 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERChief Financial Officer Feider Stephen was granted 131,543 shares and sold $17,652 worth of shares (1,428 units at $12.36), increasing direct ownership by 305% to 172,729 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERChief Product Officer Mensinger Mike was granted 109,105 shares and sold $13,153 worth of shares (1,064 units at $12.36), increasing direct ownership by 134% to 188,793 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- SECSEC Form S-3ASR filed by Beta Bionics Inc.S-3ASR - Beta Bionics, Inc. (0001674632) (Filer)
- SECSEC Form S-8 filed by Beta Bionics Inc.S-8 - Beta Bionics, Inc. (0001674632) (Filer)
BBNX FAQ
6 questionsWhere does BBNX stock trade?
Beta Bionics Inc. (BBNX) is listed on NASDAQ.What sector and industry is BBNX in?
Beta Bionics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Beta Bionics Inc. go public?
Beta Bionics Inc. (BBNX) completed its IPO in 2025.What are analysts saying about BBNX?
Beta Bionics Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $2400.00 price target on 2026-02-09. Recent price targets range from $1600.00 to $3000.00.What companies are similar to BBNX?
Notable peers in the same industry include SYK (Stryker Corporation), BSX (Boston Scientific Corporation), MMM (3M Company), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare BBNX side-by-side with any of them on Quantisnow.How can I track BBNX on Quantisnow?
Quantisnow aggregates Beta Bionics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BBNX to receive live email and push alerts on every new disclosure.